Pharmafile Logo
Pharmafocus logo
Advanced Search

Research and Development

Showing 15 posts of 9599 posts found.

UCB announces first-in-patient trial success for galvokimig in atopic dermatitis

September 18, 2025 Medical Communications, Research and Development Dermatology, UCB, atopic dermatitis, clinical trial

UCB has reported positive early clinical trial results for galvokimig, an investigational therapy for adults with moderate-to-severe atopic dermatitis (AD). …
News
mobile apps

electronRx to launch pDx app for remote monitoring of chronic respiratory disease

September 18, 2025 Research and Development Asthma & COPD, Devices, devices, electronRx, pDx, respiratory diseases (CRDs)

Digital medicine company electronRx, based in Cambridge, UK, has announced the upcoming launch of pDx, a mobile app designed to …
News

ProteoNic Biosciences launches platform to enhance cell line productivity

September 17, 2025 Research and Development Devices, ProteoNic Biosciences, cell line productivity, gene therapy

ProteoNic Biosciences, a biotech company headquartered in Leiden, Germany has unveiled its latest technology platform, the 2G UNic transposon system, developed …
News
handshake-2056023_960_720

NeoVac appoints Jan H Egberts as chief executive officer

September 17, 2025 Analytical & Laboratory Services, Business Services, Clinical Trial Services, Research and Development Devices, Lipid Nanoparticle Technology, Neovac, mRNA Therapies

NeoVac, a clinical-stage biopharma based in Abingdon, UK, has appointed Jan H Egberts as chief executive officer. The company is …
Appointment
Lilly secures conditional MHRA approval for new blood cancer treatment

Symeres announces acquisition of DGr Pharma

September 11, 2025 Medical Communications, Research and Development DGr Pharma, Symeres, biopharma, contract research

Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug development-focused consultancy. The acquisition will …
News

Danny Wolin appointed as KJT’s Senior VP of real-world evidence

September 11, 2025 Medical Communications, Research and Development KJT, real-world evidence

Danny Wolin has been appointed as Senior Vice President of Real-World Evidence at KJT. KJT is an evidence-based healthcare consulting …
Appointment

Sapio Sciences and Ultima Genomics form multi-omics research partnership

September 11, 2025 Medical Communications, Research and Development Sapio Sciences, Ultima Genomics, biotech, genomics research

Sapio Sciences and Ultima Genomics have formed a strategic partnership to accelerate genomics research. The collaboration aims to make multi-omics …
News
drug-trials

MultiOmic Health and BIO4 Campus sign collaborative Memorandum of Understanding

September 8, 2025 Medical Communications, Research and Development AI, BIO4 Campus, Memorandum of Understanding, MultiOmic Health, biotech

MultiOmic Health (MOH), an artificial intelligence (AI)-enabled precision medicine biotechnology company and BIO4 Campus (BIO4), a biotechnology and life sciences …
News

Rare and severe epilepsies – current treatments and advance therapeutics

August 29, 2025 Medical Communications, Research and Development Neurology, UCB, epilepsy, epilepsy treatment, rare epilepsies

The current forms of immunotherapy, how T cell therapy works and what the future holds
Feature
hospital

The Pharma Files: With Professor Hatim Abdulhussein from Health Innovation Kent Surrey Sussex

August 28, 2025 Medical Communications, Research and Development Corporate, GP, Health Innovation Kent Surrey Sussex, The Pharma Files

Pharmafile chats with Priyanka Hinton, Customer Solutions Director at Chase People about the best parts of her job and her …
Feature

European Commission approves HIV prevention injection

August 28, 2025 Medical Communications, Research and Development European Commission, Gilead Science, HIV, HIV/AIDS, US Food and Drug Administration, World Health Organisation

The European Commission (EC) has granted marketing authorisation for Gilead Science’s Yeytuo (lenacapavir), the first twice-yearly injectable medicine approved in …
News

EMA grants orphan drug designation for Roca’s treatment of radiation maculopathy

August 28, 2025 Medical Communications, Research and Development European Medicines Agency (EMA), Oncology, Opthalmology, Roca Therapeutics, maculopathy

The European Medicines Agency (EMA) has granted Orphan Drug Designation to Roca Therapeutics for its lead candidate RCT002, marking the …
News

Neogap Therapeutics appoints Jonas Mattson to its board of directors

August 26, 2025 Research and Development Corporate, Immunology, Neogap Therapeutics, Oncology, board of directors

Swedish biotech, Neogap Therapeutics, has appointed Jonas Mattson, an authority in cell therapy, to its board of directors. His appointment …
Appointment
hsm_mobile_clinical_trial_istock-872676342

FDA approves Wegovy for treatment of MASH in adults with liver fibrosis

August 22, 2025 Medical Communications, Research and Development Hepatology, Novo Nordisk, US Food and Drug Administration, clinical trial, hepatitis, obesity

The US Food and Drug Administration (FDA) has granted accelerated approval for Wegovy (semaglutide) as a treatment for adults with …
News
epilepsy-623346_960_720

Epilepsy Research Institute opens 2025-26 grant round with new awards

August 21, 2025 Medical Communications, Research and Development Neurology, epilepsy, funding programme, medical research

The Epilepsy Research Institute has opened its 2025-26 Grant Round, offering a wide range of funding opportunities designed to support …
News
The Gateway to Local Adoption Series

Latest content

Siemens Healthineers opens 10m euro R&D centre for laboratory equipment in Ireland

February 19, 2026

Everdrone announces new board of directors to drive expansion

February 19, 2026

Regeneron announces presentations of new data on Eylea HD for retinal disease

February 18, 2026

Indegene completes acquisition of Cake Health

February 18, 2026

Gedeon Richter UK acquires rights to schizophrenia treatment Reagila from Recordati Pharmaceuticals

February 17, 2026